DaVita Clinical Research Announces New Biorepository Services
September 13 2011 - 9:00AM
Business Wire
DaVita Clinical Research® (DCR®), a provider of clinical
research services focused on kidney research as well as a multitude
of specialty therapeutic populations, announces its one-of-a-kind
Biorepository Services. These services offer the pharmaceutical
industry unique collaborative research opportunities that combine
access to high-quality samples combined with well-characterized
patient data annotation.
DCR’s distinctive Biorepository Services support industry trends
toward personalized medicine, empowered drug discovery and
productive drug development for biotechnology and pharmaceutical
sponsors, as well as platform technology companies. This unique
approach is at the forefront of changes with the biorepository
industry that will provide meaningful advances toward the future of
more effective drug discovery and development.
“We are excited to begin this new chapter and believe the
biorepository we are creating will set a new standard in the
industry and add value to the drug discovery efforts of our
partners,” stated DCR President Chris Rucker. “We believe that the
unique characteristics of our offering will position us to meet a
need in the discovery community that is currently not being
satisfied by the existing biorepositories.”
DCR’s unique biorepository provides customized sample sets from
patient populations collected nationally. These samples are
collected under an IRB-approved protocol with the consent of
patients. The high-quality samples contain high RNA and DNA yields
and are suitable for genomic analysis. In addition, DCR collects
samples under the same rigorous conditions that allow proteomic and
metabolomic testing.
“Our unprecedented levels of operational excellence ensure that
our partners not only have a sample for testing of the highest
level of sample integrity, but the well-characterized data
associated with it, including patient health history, treatment
data, prescription data and hospitalization data,” said Dr. Mahesh
Krishnan, M.D., DCR vice president of clinical research. “It is the
characterization of our data and the annotation of this data to our
sample sets that distinguish our biorepository services from the
majority of the industry.”
With a staff that is fully committed to advancing the knowledge
and practice of kidney care, DCR brings unsurpassed knowledge,
skill and expertise to pharmaceutical research, helping facilitate
the success of clinical trials.
DaVita, DaVita Clinical Research and DCR are registered
trademarks of DaVita, Inc. All other trademarks are the property of
their respective owners.
About DaVita Clinical Research (DCR)
DaVita Clinical Research (DCR) brings unsurpassed knowledge,
skill, and expertise to pharmaceutical research, facilitating the
success of their clients’ clinical trials. DCR’s clinical expertise
ranges from designing the study to preparing and submitting the
final report. DCR’s Early Clinical Research unit (Phase I-IIa) and
Clinical Development network of physicians and investigative sites,
Health Economics and Central Laboratory are focused on providing
world-class clinical research in both complex/specialty populations
and therapeutic areas as well as CKD and ESRD populations needed to
meet clinical goals. To learn more about DCR, visit
www.davitaclinicalresearch.com.
About DaVita
DaVita Inc., a Fortune 500® company, is a leading provider of
kidney care in the United States, delivering dialysis services to
patients with chronic kidney failure and end stage renal disease.
DaVita strives to improve patients’ quality of life by innovating
clinical care, and by offering integrated treatment plans,
personalized care teams and convenient health-management services.
As of June 30, 2011, DaVita operated or provided administrative
services at 1,669 dialysis facilities, serving approximately
131,000 patients. DaVita supports numerous programs dedicated to
creating positive, sustainable change in communities around the
world. The company’s leadership development initiatives and social
responsibility efforts have been recognized by Fortune, Modern
Healthcare, Newsweek and WorldBlu. For more information, please
visit www.davita.com.
DaVita (NYSE:DVA)
Historical Stock Chart
From May 2024 to Jun 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Jun 2023 to Jun 2024